Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 12;11(8):e0161111.
doi: 10.1371/journal.pone.0161111. eCollection 2016.

Flavonoids as CDK1 Inhibitors: Insights in Their Binding Orientations and Structure-Activity Relationship

Affiliations

Flavonoids as CDK1 Inhibitors: Insights in Their Binding Orientations and Structure-Activity Relationship

Carlos Navarro-Retamal et al. PLoS One. .

Abstract

In the last years, the interactions of flavonoids with protein kinases (PKs) have been described by using crystallographic experiments. Interestingly, different orientations have been found for one flavonoid inside different PKs and different chemical substitutions lead to different orientations of the flavonoid scaffold inside one PK. Accordingly, orientation predictions of novel analogues could help to the design of flavonoids with high PK inhibitory activities. With this in mind, we studied the binding modes of 37 flavonoids (flavones and chalcones) inside the cyclin-dependent PK CDK1 using docking experiments. We found that the compounds under study adopted two different orientations into the active site of CDK1 (orientations I and II in the manuscript). In addition, quantitative structure-activity relationship (QSAR) models using CoMFA and CoMSIA methodologies were constructed to explain the trend of the CDK1 inhibitory activities for the studied flavonoids. Template-based and docking-based alignments were used. Models developed starting from docking-based alignment were applied for describing the whole dataset and compounds with orientation I. Adequate R2 and Q2 values were obtained by each method; interestingly, only hydrophobic and hydrogen bond donor fields describe the differential potency of the flavonoids as CDK1 inhibitors for both defined alignments and subsets. Our current application of docking and QSAR together reveals important elements to be drawn for the design of novel flavonoids with increased PK inhibitory activities.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Structures of flavones (1–19) and chalcones (20–37).
Fig 2
Fig 2. Binding modes of the compounds under study into CDK1 binding site.
(A) flavones, compounds 119 (B) chalcones with orientation I, compounds 3137, (C) chalcones with orientation II, compounds 2030.
Fig 3
Fig 3. Template alignment (TA) for all compounds used for CoMFA and CoMSIA.
Fig 4
Fig 4
Scatter plot of the experimental activities versus predicted activities for the best CoMSIA models using TA (A), DA (B) and DAI (C). (●) training-set predictions, (○) LOO cross-validated predictions, (×) test-set predictions.
Fig 5
Fig 5
CoMSIA contour maps for CDK1 inhibitors deriving from the best models for the TA (A), DA (B) and DAI (C) alignments. Compound 20 is shown inside the fields in (A) and (B), and compound 4 is shown inside the fields in (C). In (B) and (C), the amino acid residues located close to the binding pocket of CDK1 are represented for comparing their position with the position of isopleths derived from the model. Hydrophobic field: yellow isopleths indicate regions where hydrophobic groups favor the activity, and gray isopleths indicate regions where hydrophilic groups favor the activity. HB donor field: cyan isopleths indicate regions where HB donors favor the activity, and purple isopleths indicate regions where HB donors disfavor the activity. Steric field (in C): green isopleths indicates region where bulky groups favor the activity.

Similar articles

Cited by

References

    1. Hollman PC, Katan MB. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 1999;37: 937–942. - PubMed
    1. Boam T. Anti-androgenic effects of flavonols in prostate cancer. Ecancermedicalscience. 2015;9: 585 10.3332/ecancer.2015.585 - DOI - PMC - PubMed
    1. Vidak M, Rozman D, Komel R. Effects of Flavonoids from Food and Dietary Supplements on Glial and Glioblastoma Multiforme Cells. Mol Basel Switz. 2015;20: 19406–19432. 10.3390/molecules201019406 - DOI - PMC - PubMed
    1. Srinivas NR. Recent trends in preclinical drug-drug interaction studies of flavonoids—Review of case studies, issues and perspectives. Phytother Res PTR. 2015;29: 1679–1691. 10.1002/ptr.5447 - DOI - PubMed
    1. Turati F, Rossi M, Pelucchi C, Levi F, La Vecchia C. Fruit and vegetables and cancer risk: a review of southern European studies. Br J Nutr. 2015;113 Suppl 2: S102–110. 10.1017/S0007114515000148 - DOI - PubMed

LinkOut - more resources